Eloralintide
Selective long-acting amylin receptor agonist (C20 fatty-diacid conjugated amylin analog)
- Class
- Selective amylin agonist
- Half-life
- ~2 weeks
- Route
- Subcutaneous (SubQ)
- Cadence
- Weekly
- Evidence
- Human clinical trials
Overview
Eloralintide is Eli Lilly's bet on a different satiety pathway than the GLP-1 drugs dominating the weight-loss space right now. It's a selective amylin receptor agonist — the first to make it to phase-2 testing as a standalone obesity drug. Once-weekly subcutaneous injection (same cadence as semaglutide or tirzepatide), and in Lilly's 48-week phase-2 trial the highest dose (9 mg weekly) averaged about 20% body-weight loss. That's in the same ballpark as tirzepatide, but through a different mechanism.
Amylin is a hormone your pancreas co-secretes with insulin. It slows stomach emptying, tells your brain you're full, and tamps down glucagon (the hormone that raises blood sugar). Native amylin breaks down in minutes and clumps into fibrils if you try to extend it. Eloralintide is a stabilised analog with a C20 fatty-acid tail that binds albumin reversibly — same half-life extension strategy semaglutide uses. Crucially, it hits amylin receptors hard but largely avoids the calcitonin receptor. That selectivity is the pitch: less nausea than older amylin drugs like cagrilintide (which activates both) and better lean-mass preservation than GLP-1s.
As of mid-2026, Lilly is enrolling phase-3 monotherapy trials and also testing eloralintide stacked with tirzepatide. The stacking angle is the real strategic play — amylin and incretin pathways are mechanistically separate, so combining them may push total weight loss even higher without overlapping side effects. It's not approved anywhere yet, but research-market sellers jumped on it the moment Lilly published the phase-2 data.
Safety considerations
A few of the safety signals worth knowing — the full list, with dosing context and what to monitor, is inside AIx Core.
- Not approved anywhere. Sold in research markets as LY3841136 — purity and dose accuracy are unregulated.
- Phase-1 and phase-2 trials reported mild-to-moderate GI side effects (nausea, fatigue) more often in higher-dose arms, but discontinuation rates were low. Lilly claims better GI tolerability than cagrilintide, but no human head-to-head exists.
- Amylin agonists can raise heart rate modestly (mechanism: area-postrema-mediated sympathetic tone). Monitor resting HR, especially if stacking with stimulants or other HR-raising compounds.
+ 3 more safety notes inside AIx Core →
Commonly monitored
Markers and signals people track when researching Eloralintide.
- Body composition (DEXA or BIA) — lean mass preservation is a claimed advantage
- Resting heart rate (amylin agonists can raise it modestly)
- HbA1c if using for diabetes / prediabetes
- Lipid panel
- Subjective GI tolerance during titration (nausea, bloating, constipation)
- Appetite / 'food noise' changes (main subjective signal for efficacy)
Frequently asked questions
What is Eloralintide?
Selective long-acting amylin receptor agonist (C20 fatty-diacid conjugated amylin analog). Eloralintide is Eli Lilly's bet on a different satiety pathway than the GLP-1 drugs dominating the weight-loss space right now. It's a selective amylin receptor agonist — the first to make it to phase-2 testing as a standalone obesity drug. Once-weekly subcutaneous injection (same cadence as semaglutide or tirzepatide), and in Lilly's 48-week phase-2 trial the highest dose (9 mg weekly) averaged about 20% body-weight loss. That's in the same ballpark as tirzepatide, but through a different mechanism.
How is Eloralintide administered?
Subcutaneous (SubQ), typically weekly.
What is the half-life of Eloralintide?
~2 weeks — C20 fatty-diacid conjugate binds albumin reversibly, yielding a half-life of ~2 weeks — enables once-weekly dosing.
Is Eloralintide approved for human use?
Eloralintide is investigational — not approved by the FDA, EMA, or MHRA for human use at the time of writing.
What does the evidence show for Eloralintide?
Evidence tier: Human clinical trials. Billings et al., Lancet 2025 (phase-2, n=263, 48 weeks): 9 mg weekly dose averaged -20.1% body weight vs -0.4% placebo. Lower doses (1.5 mg, 3 mg, 6 mg) ranged from -9.5% to -13.8%.
What is commonly monitored when researching Eloralintide?
Commonly tracked markers + signals: Body composition (DEXA or BIA) — lean mass preservation is a claimed advantage, Resting heart rate (amylin agonists can raise it modestly), HbA1c if using for diabetes / prediabetes, Lipid panel, Subjective GI tolerance during titration (nausea, bloating, constipation), Appetite / 'food noise' changes (main subjective signal for efficacy).
Related compounds
Open this in AIx Core for the full picture
Mechanism breakdown, receptor pathway diagram, full safety list, monitored items, source citations, and one-tap add-to-protocol. Free with any account.